Lung Cancer Treatments and Mutations

Lung cancer kills more people annually than any other cancer, and a key reason researchers have made meaningful progress against it is the discovery that many tumors are driven by specific genetic mutations—particularly in the EGFR gene and the ALK gene—that can be targeted with drugs designed to block those molecular signals rather than simply poisoning all dividing cells. Genomic profiling now allows clinicians to match patients to therapies based on the molecular signature of their tumor, a shift that has turned some previously dire diagnoses into manageable chronic conditions. The central challenge the field grapples with is resistance: tumors almost inevitably evolve workarounds to targeted inhibitors, and understanding the mechanisms behind that resistance—whether through secondary mutations, bypass signaling pathways, or histological transformation—is one of the most active areas of current investigation. Ongoing clinical trials are testing combination strategies, next-generation inhibitors, and immunotherapy pairings in an effort to extend durable responses and address the substantial fraction of patients whose tumors lack known actionable mutations.

Works

130,079

Total citations

1,690,294

Keywords

EGFR MutationsTargeted TherapyALK InhibitorsResistance MechanismsClinical TrialsGenomic Profiling